Ralph DeFronzo, MD
The University of Texas Health Science Center at San Antonio · University of Texas Health San Antonio · University of Texas Health at San Antonio
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ralph DeFronzo, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:00 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07925801 · Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionThe University of Texas Health Science Center at San Antonio · not yet recruiting · Type 2 Diabetes, Hypercortisolism · principal investigator
- Ph3NCT07056699 · SGLT2i, Pioglitazone, and Ketone Production in T1DThe University of Texas Health Science Center at San Antonio · recruiting · Type1diabetes · principal investigator
- Early Ph1NCT07053293 · SGLT2i, Hepatic Glucose Production, and SNSThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Ph1NCT07053306 · SGLT2i, Ketoacidosis, Volume Contraction, and InsulinopeniaThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Ph1NCT07053319 · SGLT2i, Pioglitazone, and Ketone Production in T2DThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Early Ph1NCT06229678 · Ketones, SGLT2, HFrEFThe University of Texas Health Science Center at San Antonio · recruiting · Type2diabetes, Heart Failure With Reduced Ejection Fraction · principal investigator
- Ph1NCT05960656 · SGLTi, Hepatic Glucose Production and KetogenesisThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- N/ANCT05867017 · Long-Term Sequelae of SARS-COV-2 Infection: Diabetes MellitusThe University of Texas Health Science Center at San Antonio · completed · COVID-19, Diabete Mellitus · principal investigator
- Early Ph1NCT05093517 · Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DMThe University of Texas Health Science Center at San Antonio · completed · Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity · principal investigator
- N/ANCT04791787 · Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 DiabetesThe University of Texas Health Science Center at San Antonio · completed · Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes · principal investigator
- Early Ph1NCT04300049 · Effect of Physiologic Hyperglucogonemia on Adipocyte MetabolismThe University of Texas Health Science Center at San Antonio · completed · Insulin Sensitivity · principal investigator
- N/ANCT03953963 · Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 DiabetesMedality Medical · unknown · Diabetes Mellitus, Type 2, Insulin Resistance · principal investigator
- Ph4NCT02911792 · Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With HyperfiltrationThe University of Texas Health Science Center at San Antonio · completed · Diabetes Mellitus, Type 2 · principal investigator
- N/ANCT01439854 · Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/ActionThe University of Texas Health Science Center at San Antonio · completed · Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome · principal investigator
- Ph4NCT01107717 · Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMThe University of Texas Health Science Center at San Antonio · completed · Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 44 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · fiscal years 1986 to 2026
- Ketones, Muscle Metabolism, and SGLT2 InhibitorsR01DK107680 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · fiscal years 2016 to 2026Named on NCT06229678
- OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Rachel Sharon Gross, Leora Horwitz, STUART D KATZ, Andrea B Troxel · fiscal years 2021 to 2025Named on NCT05867017
- Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DMR01DK103841 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · fiscal years 2015 to 2017Named on NCT01107717
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.